Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Direct Meds vs Vytora Health

Direct Meds
Graded #19

Higher grade

vs+10.299999999999997
Vytora Health
Graded #79

Lower grade

The verdict

Direct Meds takes it — 82.6/100 to 72.3/100.

Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueDirect Meds +26
85
59
Dose & formulationDirect Meds +3
88
85
Clinical oversightVytora Health +16
80
96
Labs & monitoringDirect Meds +23
78
55
FulfillmentVytora Health +16
80
96
Contract termsDirect Meds +60
80
20
Direct Meds · left barVytora Health · right bar

The numbers

MetricDirect MedsVytora Health
WeighScore82.6/10072.3/100
GradeB−C
Scorecard rank#19#79
Semaglutide$179/mo$180/mo (all doses, compounded)
Tirzepatide$224/mo$249/mo (all doses, compounded)
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Direct Meds

Graded #19 · B−

Strengths

  • Rare oral/sublingual option in addition to injectable
  • All-inclusive pricing with no separate membership fee
  • Both molecules — semaglutide and tirzepatide
  • Intro promotional pricing near $147

Where it loses points

  • Compounded only — not FDA-approved
  • Pricing is company-stated, not independently live-verified
  • Newer and somewhat ambiguous (operates across multiple domains)
  • States served are not disclosed
Vytora Health

Graded #79 · C

Strengths

  • All 50 states plus DC, with per-state video-vs-audio compliance disclosed
  • Both compounded and brand-name options on one platform — uncommon
  • LegitScript Approved and HIPAA compliant
  • Pharmacy partners named publicly: Vials Pharmacy (TX) and Greenwich Biosciences
  • Operating entity disclosed: Wasef Health, PC (Pinellas Park, FL)

Where it loses points

  • Brand-name Mounjaro/Zepbound at $1,399/mo is near retail — insured patients may do better via LillyDirect Self Pay ($449-$699/mo)
  • Compounded tirzepatide at $249/mo is mid-market, above the $149-199 floor
  • Dose tiers aren't broken out — 'all doses included' means low-dose patients pay the same as high-dose
  • Initial consultation cost not shown on the public pricing page
  • Limited per-prescriber state licensure detail

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard